DexCom reported strong Q3 2026 financial results, exceeding both revenue and EPS analyst estimates. The company subsequently raised its full-year 2026 revenue guidance, indicating robust performance in its continuous glucose monitoring business, which is likely to be viewed positively by investors.
DexCom announced Q3 2026 revenue of $1.34 billion, surpassing the FactSet consensus of $1.33 billion, and adjusted EPS of $0.73, beating estimates of $0.67. This strong performance led the company to raise its full-year 2026 revenue guidance to $5.20 billion-$5.25 billion. This is a significant positive catalyst for DexCom, as it demonstrates continued growth and market penetration in its core continuous glucose monitoring business. Investors will likely react positively to both the beat and the improved outlook, suggesting potential short-term upside for DXCM stock. The long-term implication is a reinforced positive sentiment for the company's growth trajectory in the diabetes management sector, though competitive pressures remain a key risk.